Craig W. Philips Takes Helm at CTI (ment of non-Hodgkin's lymphoma (NHL) and...)

Craig W. Philips Takes Helm at CTI

Date:8/4/2008

ment of non-Hodgkin's lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed by CTI to improve the activity and safety in treating cancers usually treated with the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types, such as lymphoma, leukemia, and breast cancer. For these diseases, anthracycline-containing chemotherapy regimens are effective in first-line (initial) treatment. However, they may cause cumulative heart damage that limits lifetime dosage and does not allow for retreatment. Pixantrone has been designed to reduce the potential for heart damage compared to currently available anthracyclines or anthracenediones without a loss in anti-tumor or immunomodulatory activities.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Non-Hodgkin's Lymphoma

Non-Hodgkin's lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drai
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Queen Latifahs Travlin Light Tour to Be Sponsored by Jenny Craig
2. Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney
3. Jenny Craig Offers Help to Stranded Clients
4. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
5. Cardinal Health Names Former Acting Deputy U.S. Attorney General Craig S. Morford to Chief Compliance Officer Post
6. J. Craig Venter, Human Genome Pioneer, to Receive Award at Vietnam Veterans of Americas National Leadership Conference
7. Jenny Craig Establishes License Agreement for Volumetrics(R)
8. VASAMED(R) Appoints Craig M. Walker, MD to Board of Directors
9. MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners
10. Audio from Medialink and Philips: Americas Dirty Mouths
11. AUDIO from Medialink and Philips: Getting Rid of the Uninvited Holiday Guests on Your Toothbrush

Post Your Comments:

Craig W. Philips Takes Helm at CTI(ment of non-Hodgkin's lymphoma (NHL) and...),Health